Latest Headlines

  1. Lonza Opens Cell And-Gene-Therapy Center Of Excellence In Texas

    Lonza reported it opened “the world’s largest dedicated cell and-gene-therapy Center of Excellence,” in Pearland, Texas. The COE is expected to reach 200 full-time staff by end of 2018 in greater Houston and continue to recruit high-value positions as market demand increases.

  2. Extract Technology To Exhibit Cell Therapy Isolator At PDA Cell And Gene Therapy Conference

    The 2018 PDA Cell and Gene Therapy Conference (October 23-24) will provide a broad overview of current innovations with a focus on what it takes to successfully steward these therapies toward approval and beyond.

  3. MilliporeSigma Offers Rhabdovirus-Free Insect Platform For Viral Vaccines And Gene Therapy Development

    MilliporeSigma is collaborating with GlycoBac LLC to offer a Sf-9 insect cell line. GlycoBac’s development of a proven rhabdovirus-negative (RVN) cell line enables MilliporeSigma to offer the first Sf-9 platform combining a rhabdovirus-free insect cell line with a corresponding, chemically defined cell culture medium. This will be the first non-mammalian cell line in MilliporeSigma’s cell culture portfolio, allowing customers worldwide access to a safer, high-performing vehicle for recombinant protein expression, Virus-like Particle vaccines and Adeno Associated Virus based gene therapy production.

  4. Rubius Therapeutics To Invest $155M Into New Cell Therapy Drug Manufacturing Facility In RI

    Rubius Therapeutics is investing $155M on a newly designed pharmaceutical manufacturing facility in Smithfield, Rhode Island.

  5. Novo Nordisk To Establish Manufacturing Site In California For Stem Cell-Based Drug Therapies

    Novo Nordisk recently announced the establishment of a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. The announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previously operated by Asterias Biotherapeutics.

  6. Brammer Bio Announces Progress On $200 Million Program To Advance Gene Therapies

    Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO), announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.

  7. Cobra Biologics, GE Healthcare And Centre For Process Innovation Collaborate To Advance Gene Therapy

    Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, announced a collaboration with the Centre for Process Innovation (CPI), a UK-based technology innovation centre and GE Healthcare Life Sciences. The three-way partnership, funded by a £570K Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments. The gene therapy area has been developing rapidly and while only a small number of treatments are already approved for use, more than 200 clinical trials are underway.

  8. IPS And G-CON Launch iCON Cell Therapy Platform with Shipment Of The 1st ÜBERcellFLEX PODs

    Following up on the launch of the iCON Turnkey Facility Platform for a mAb manufacturing facility late last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing have successfully designed and delivered the first ÜBERcellFLEX PODs for the manufacturing of autologous cell therapies. The iCON solution provides a pre-fabricated modular cleanroom infrastructure for the drug manufacturers’ requirements for both clinical and commercial manufacture of critical therapies.

  9. Pall Corporation And Celltheon Form Strategic Partnership For Biotherapeutics Development And Manufacturing With CELLTHEON SMART™ Expression Platform

    Pall Corporation, a global leader in filtration, separation and purification, has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company. This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMARTTM Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. It is part of Pall’s strategic approach to forming key partnerships that help enable better, safer and faster biologic production.

  10. Scaling Up Cell Therapy Manufacturing In Guangzhou

    GE Healthcare FlexFactory Helps XPH Scale Up Industrialization of TCR T Cell Immunotherapy Drugs.